Refine by
Disease Progression Service Provider
4 companies found
Service providerbased in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
T cells play a vital role in destroying pathogens and monitoring pathological cells. They are able to distinguish between self-antigens and non-self-antigens by surface T cell receptors (TCRs). Most human T cells express the classical TCRs, which ...
Service providerbased inDüsseldorf, GERMANY
The biotech research company was founded in 1993 and employs around 20 people with various scientific qualifications and experiences. Orthogen AG is a privately held Holdings Company located in Dusseldorf, Germany where its founder and CEO, Prof. ...
The musculoskeletal system of animals, especially companion animals such as horses or dogs as well as minor species such as mice and rats, is fundamentally similar to the musculoskeletal system of humans. Biomolecular changes underlying orthopedic ...
Service providerbased inYardley, PENNSYLVANIA (USA)
MMIT, a Norstella company, focuses on enhancing market access for pharmaceutical companies by offering real-time data and insights as well as crucial commercial execution strategies. With decades of experience, MMIT has evolved from its origins as ...
MMIT and its parent company Norstella transform physician clinical notes, specialty consultations and other unstructured EMR notes into longitudinal, analytic-ready ...
Service providerbased inCambridge, MASSACHUSETTS (USA)
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with ...
The first patient was dosed with our investigational genome editing treatment for transthyretin (ATTR) amyloidosis in November 2020. Our modular approach enables us to optimize the power and versatility of the CRISPR/Cas9 technology and, ...